Kim Dong Hwa, Huegel Julianne, Taylor Brittany L, Nuss Courtney A, Weiss Stephanie N, Soslowsky Louis J, Mauck Robert L, Kuntz Andrew F
Department of Orthopaedic Surgery, University of Pennsylvania, McKay Orthopaedic Research Laboratory, 36th Street and Hamilton Walk, 374 Stemmler Hall, Philadelphia, PA 19104-6081, USA; Translational Musculoskeletal Research Center, Philadelphia VA Medical Center, 3900 Woodland Avenue, Building 21, Room A200, Philadelphia, PA 19104, USA.
Department of Orthopaedic Surgery, University of Pennsylvania, McKay Orthopaedic Research Laboratory, 36th Street and Hamilton Walk, 374 Stemmler Hall, Philadelphia, PA 19104-6081, USA; Translational Musculoskeletal Research Center, Philadelphia VA Medical Center, 3900 Woodland Avenue, Building 21, Room A200, Philadelphia, PA 19104, USA; Department of Bioengineering, University of Pennsylvania, 210 South 33rd Street, Suite 240, Skirkanich Hall, Philadelphia, PA 19104-6321, USA.
Acta Biomater. 2020 Jul 15;111:341-348. doi: 10.1016/j.actbio.2020.04.048. Epub 2020 May 16.
Many drug delivery systems rely on degradation or dissolution of the carrier material to regulate release. In cases where mechanical support is required during regeneration, this necessitates composite systems in which the mechanics of the implant are decoupled from the drug release profile. To address this need, we developed a system in which microspheres (MS) were sequestered in a defined location between two nanofibrous layers. This bilayer delivery system (BiLDS) enables simultaneous structural support and decoupled release profiles. To test this new system, PLGA (poly-lactide-co-glycolic acid) microspheres were prepared using a water-in-oil-in-water (w/o/w) emulsion technique and incorporated Alexa Fluor-tagged bovine serum albumin (BSA) and basic fibroblast growth factor (bFGF). These MS were secured in a defined pocket between two polycaprolactone (PCL) nanofibrous scaffolds, where the layered scaffolds provide a template for new tissue formation while enabling independent and local release from the co-delivered MS. Scanning electron microscopy (SEM) images showed that the assembled BiLDS could localize and retain MS in the central pocket that was surrounded by a continuous seal formed along the margin. Cell viability and proliferation assays showed enhanced cell activity when exposed to BiLDS containing Alexa Fluor-BSA/bFGF-loaded MS, both in vitro and in vivo. MS delivered via the BiLDS system persisted in a localized area after subcutaneous implantation for at least 4 weeks, and bFGF release increased colonization of the implant. These data establish the BiLDS technology as a sustained in vivo drug delivery platform that can localize protein and other growth factor release to a surgical site while providing a structural template for new tissue formation. STATEMENT OF SIGNIFICANCE: Localized and controlled delivery systems for the sustained release of drugs are essential. Many strategies have been developed for this purpose, but most rely on degradation (and loss of material properties) for delivery. Here, we developed a bilayer delivery system (BiLDS) that decouples the physical properties of a scaffold from its delivery kinetics. For this, biodegradable PLGA microspheres were sequestered within a central pocket of a slowly degrading nanofibrous bilayer. Using this device, we show enhanced cell activity with FGF delivery from the BiLDS both in vitro and in vivo. These data support that BiLDS can localize sustained protein and biofactor delivery to a surgical site while also serving as a mechanical scaffold for tissue repair and regeneration.
许多药物递送系统依靠载体材料的降解或溶解来调节释放。在再生过程中需要机械支撑的情况下,这就需要复合系统,其中植入物的力学性能与药物释放曲线解耦。为满足这一需求,我们开发了一种系统,将微球(MS)隔离在两个纳米纤维层之间的特定位置。这种双层递送系统(BiLDS)能够同时提供结构支撑和解耦的释放曲线。为测试这个新系统,使用水包油包水(w/o/w)乳液技术制备了聚乳酸-乙醇酸共聚物(PLGA)微球,并掺入了Alexa Fluor标记的牛血清白蛋白(BSA)和碱性成纤维细胞生长因子(bFGF)。这些微球被固定在两个聚己内酯(PCL)纳米纤维支架之间的特定腔室中,其中分层支架为新组织形成提供模板,同时允许从共同递送的微球中独立且局部地释放。扫描电子显微镜(SEM)图像显示,组装好的BiLDS能够将微球定位并保留在中央腔室中,该腔室被沿边缘形成的连续密封包围。细胞活力和增殖测定表明,在体外和体内,当暴露于含有载有Alexa Fluor-BSA/bFGF的微球的BiLDS时,细胞活性增强。通过BiLDS系统递送的微球在皮下植入后至少4周内在局部区域持续存在,并且bFGF的释放增加了植入物的定植。这些数据确立了BiLDS技术作为一种持续的体内药物递送平台,它可以将蛋白质和其他生长因子的释放定位到手术部位,同时为新组织形成提供结构模板。重要性声明:用于药物持续释放的局部和可控递送系统至关重要。为此已经开发了许多策略,但大多数依赖于降解(以及材料性能的丧失)来进行递送。在这里,我们开发了一种双层递送系统(BiLDS),它将支架的物理性能与其递送动力学解耦。为此,将可生物降解的PLGA微球隔离在缓慢降解的纳米纤维双层的中央腔室中。使用这个装置,我们在体外和体内均显示出从BiLDS递送FGF时细胞活性增强。这些数据支持BiLDS可以将持续的蛋白质和生物因子递送定位到手术部位,同时还作为组织修复和再生的机械支架。